Article Sidebar
Main Article Content
LncRNA SNHG4 Regulates Lipid Metabolism and Inflammation in Non-Alcoholic Fatty Liver Disease by Targeting miR-34b-5p/XIAP Axis
Main Article Content
Abstract
Background/Aims: This research aimed at probing the mechanism of long non-coding RNA small nucleolar RNA host gene 4 (SNHG4) in regulating lipid metabolism and inflammation in non-alcoholic fatty liver disease (NAFLD).
Materials and Methods: L02 and THLE-2 cells were stimulated with free fatty acids (FFA) and transfected. Lipid accumulation was detected through Oil Red O staining, measurements of triglyceride and total cholesterol were taken, and the levels of tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 were assessed using enzyme-linked immunosorbent assays. The assessment of gene expression was conducted using real-time reverse transcriptase-polymerase chain reaction and Western blot techniques. The interplay between SNHG4 and miR-34b-5p/X-linked inhibitor of apoptosis protein (XIAP) was evaluated.
Results: Free fatty acids downregulated SNHG4 and XIAP and upregulated miR-34b-5p in L02 and THLE-2 cells, leading to lipid metabolism disorder and inflammation. SNHG4 overexpression mitigated the lipid metabolism disorder and inflammation triggered by FFA, while this effect was suppressed by silencing XIAP. In contrast, SNHG4 knockdown aggravated FFA-induced lipid metabolic and inflammatory disorders, whilst this effect was rescued by inhibiting miR-34b-5p.
Conclusion: SNHG4 regulates lipid metabolism and inflammatory disorders in NAFLD by targeting the miR-34b-5p/XIAP axis.
Cite this article as: Ding Y, Zheng S, Fu XN, Ma C, Yang J. LncRNA SNHG4 regulates lipid metabolism and inflammation in nonalcoholic fatty liver disease by targeting miR-34b-5p/XIAP axis. Turk J Gastroenterol. Published online May 5, 2025. doi 10.5152/tjg.2025.24191.
Article Details
References
1. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-S64. [CrossRef]
2. Marušić M, Paić M, Knobloch M, Liberati Pršo AM. NAFLD, insulin resistance, and diabetes mellitus Type 2. Can J Gastroenterol Hepatol. 2021;2021:6613827. [CrossRef]
3. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038-1048. [CrossRef]
4. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212-2224. [CrossRef]
5. Rong L, Zou J, Ran W, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne). 2022;13:1087260. [CrossRef]
6. Matboli M, Gadallah SH, Rashed WM, et al. mRNA-miRNA-lncRNA regulatory network in nonalcoholic fatty liver disease. Int J Mol Sci. 2021;22(13):6770. [CrossRef]
7. Rohilla S, Kaur S, Puria R. Long non-coding RNA in Non-alcoholic fatty liver disease. Adv Clin Chem. 2022;110:1-35. [CrossRef]
8. Sulaiman SA, Muhsin NIA, Jamal R. Regulatory non-coding RNAs network in non-alcoholic fatty liver disease. Front Physiol. 2019;10:279. [CrossRef]
9. Xiang J, Deng YY, Liu HX, Pu Y. LncRNA MALAT1 promotes PPARalpha/CD36-mediated hepatic lipogenesis in nonalcoholic fatty liver disease by modulating miR-206/ARNT axis. Front Bioeng Biotechnol. 2022;10:858558. [CrossRef]
10. Jin SS, Lin CJ, Lin XF, Zheng JZ, Guan HQ. Silencing lncRNA NEAT1 reduces nonalcoholic fatty liver fat deposition by regulating the miR-139-5p/c-Jun/SREBP-1c pathway. Ann Hepatol. 2022;27(2):100584. [CrossRef]
11. Liu L, Sun S, Li X. LncRNA ZFAS1 ameliorates injury led by nonalcoholic fatty liver disease via suppressing lipid peroxidation and inflammation. Clin Res Hepatol Gastroenterol. 2023;47(1):102067. [CrossRef]
12. Chu Q, Gu X, Zheng Q, et al. Long noncoding RNA SNHG4: a novel target in human diseases. Cancer Cell Int. 2021;21(1):583. [CrossRef]
13. Cao J, Xiao C, Fong CTH, et al. Expression and regulatory network analysis of function of small nucleolar RNA Host Gene 4 in Hepatocellular Carcinoma. J Clin Transl Hepatol. 2022;10(2):297-307. [CrossRef]
14. Yang Z, Tang N, Zheng M, Chang Y. Exosomal Long noncoding RNAs serve as biomarkers for liver disease. Turk J Gastroenterol. 2023;34(7):674-680. [CrossRef]
15. Yang S, Zhang Y, Zhang Y, et al. LncRNA Gm28382 promotes lipogenesis by interacting with miR-326-3p to regulate ChREBP signaling pathway in NAFLD. Int Immunopharmacol. 2024;127:111444. [CrossRef]
16. Hu MJ, Long M, Dai RJ. Acetylation of H3K27 activated lncRNA NEAT1 and promoted hepatic lipid accumulation in non-alcoholic fatty liver disease via regulating miR-212-5p/GRIA3. Mol Cell Biochem. 2022;477(1):191-203. [CrossRef]
17. Qiu N, Xu X, He Y. LncRNA TUG1 alleviates sepsis-induced acute lung injury by targeting miR-34b-5p/GAB1. BMC Pulm Med. 2020;20(1):49. [CrossRef]
18. Zheng C, Wu D, Shi S, Wang L. miR-34b-5p promotes renal cell inflammation and apoptosis by inhibiting aquaporin-2 in sepsis-induced acute kidney injury. Ren Fail. 2021;43(1):291-301. [CrossRef]
19. Hanifeh M, Ataei F. XIAP as a multifaceted molecule in cellular Signaling. Apoptosis. 2022;27(7-8):441-453. [CrossRef]
20. Zilu S, Qian H, Haibin W, et al. Effects of XIAP on high fat diet-induced hepatic steatosis: a mechanism involving NLRP3 inflammasome and oxidative stress. Aging (Albany NY). 2019;11(24):12177-12201. [CrossRef]
21. Yadav AK, Sata TN, Verma D, et al. Free fatty acid-induced miR-181a-5p stimulates apoptosis by targeting XIAP and Bcl2 in hepatic cells. Life Sci. 2022;301:120625. [CrossRef]
22. Chen S, Song P, Wang Y, et al. CircMAPK9 promotes adipogenesis through modulating hsa-miR-1322/FTO axis in obesity. iScience. 2023;26(10):107756. [CrossRef]
23. Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851-1864. [CrossRef]
24. Engin A. Non-alcoholic fatty liver disease. Adv Exp Med Biol. 2017;960:443-467. [CrossRef]
25. Park M, Yoo JH, Lee YS, Lee HJ. Lonicera caerulea extract attenuates non-alcoholic fatty liver disease in free fatty acid-induced HepG2 hepatocytes and in high fat diet-fed mice. Nutrients. 2019;11(3):494. [CrossRef]
26. Lee MR, Yang HJ, Park KI, Ma JY. Lycopus lucidus Turcz. ex Benth. attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice. Phytomedicine. 2019;55:14-22. [CrossRef]
27. Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62(3):720-733. [CrossRef]
28. Fondevila MF, Fernandez U, Heras V, et al. Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis. J Hepatol. 2022;77(1):15-28. [CrossRef]
29. Phillips MC. Is ABCA1 a lipid transfer protein? J Lipid Res. 2018;59(5):749-763. [CrossRef]
30. Babashamsi MM, Koukhaloo SZ, Halalkhor S, Salimi A, Babashamsi M. ABCA1 and metabolic syndrome; a review of the ABCA1 role in HDL-VLDL production, insulin-glucose homeostasis, inflammation and obesity. Diabetes Metab Syndr. 2019;13(2):1529-1534. [CrossRef]
31. Raeman R. Inflammation: the straw that broke the NAFLD liver! Cell Mol Gastroenterol Hepatol. 2022;13(4):1273-1274. [CrossRef]
32. Xia C, Zhu L, Shao W, et al. The effect of hippocampal cognitive impairment and XIAP on glucose and lipids metabolism in rats. Cell Physiol Biochem. 2016;38(2):609-618. [CrossRef]
33. Leung DTH, Rainczuk A, Nguyen T, et al. Targeting XIAP and PPARgamma in granulosa cell tumors alters metabolic signaling. J Proteome Res. 2019;18(4):1691-1702. [CrossRef]